Advertisement
Advertisement

XERS

XERS logo

Xeris Biopharma Holdings, Inc. Common Stock

7.02
USD
Sponsored
+0.11
+1.56%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

7.01

-0.01
-0.11%

XERS Earnings Reports

Positive Surprise Ratio

XERS beat 16 of 30 last estimates.

53%

Next Report

Date of Next Report
Mar 04, 2026
Estimate for Q4 25 (Revenue/ EPS)
$83.99M
/
$0.04
Implied change from Q3 25 (Revenue/ EPS)
+12.92%
/
--
Implied change from Q4 24 (Revenue/ EPS)
+39.75%
/
-233.33%

Xeris Biopharma Holdings, Inc. Common Stock earnings per share and revenue

On Nov 06, 2025, XERS reported earnings of 0.00 USD per share (EPS) for Q3 25, missing the estimate of 0.00 USD, resulting in a -100.00% surprise. Revenue reached 74.38 million, compared to an expected 75.66 million, with a -1.70% difference. The market reacted with a -21.88% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 analysts forecast an EPS of 0.04 USD, with revenue projected to reach 83.99 million USD, implying an -- of --% EPS, and increase of 12.92% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Xeris Biopharma Holdings, Inc. Common Stock reported EPS of $0.00, missing estimates by -100%, and revenue of $74.38M, -1.7% below expectations.
The stock price moved down -21.88%, changed from $9.87 before the earnings release to $7.71 the day after.
The next earning report is scheduled for Mar 04, 2026.
Based on 8 analysts, Xeris Biopharma Holdings, Inc. Common Stock is expected to report EPS of $0.04 and revenue of $83.99M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement